Lineage Cell Therapeutics, Inc. (TLV:LCTX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 567.50
-1.30 (-0.23%)
At close: Mar 9, 2026
Lineage Cell Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 40.79 | 45.79 | 35.44 | 11.36 | 55.74 | Upgrade
|
| Short-Term Investments | 14.99 | 2.02 | 0.05 | 46.52 | 2.62 | Upgrade
|
| Cash & Short-Term Investments | 55.78 | 47.81 | 35.49 | 57.88 | 58.36 | Upgrade
|
| Cash Growth | 16.68% | 34.69% | -38.67% | -0.83% | 40.41% | Upgrade
|
| Accounts Receivable | 1.56 | 0.64 | 0.75 | 0.3 | 50.84 | Upgrade
|
| Receivables | 1.56 | 0.64 | 0.75 | 0.3 | 50.84 | Upgrade
|
| Prepaid Expenses | 1.79 | 2.55 | 2.2 | 1.83 | 2.35 | Upgrade
|
| Other Current Assets | 0.02 | - | - | - | - | Upgrade
|
| Total Current Assets | 59.16 | 51 | 38.44 | 60 | 111.55 | Upgrade
|
| Property, Plant & Equipment | 4.7 | 4.4 | 4.77 | 5.67 | 4.87 | Upgrade
|
| Goodwill | 10.67 | 10.67 | 10.67 | 10.67 | 10.67 | Upgrade
|
| Other Intangible Assets | 31.7 | 46.54 | 46.56 | 46.69 | 46.82 | Upgrade
|
| Long-Term Deferred Tax Assets | 5.8 | - | - | - | - | Upgrade
|
| Other Long-Term Assets | 0.56 | 0.61 | 0.58 | 0.63 | 0.63 | Upgrade
|
| Total Assets | 112.58 | 113.22 | 101.02 | 123.66 | 174.55 | Upgrade
|
| Accounts Payable | 2.34 | 1.17 | 2.05 | 2.39 | 3.54 | Upgrade
|
| Accrued Expenses | 4.84 | 4.26 | 4.22 | 6.22 | 24.25 | Upgrade
|
| Current Portion of Leases | 0.85 | 1.15 | 0.88 | 0.95 | 0.83 | Upgrade
|
| Current Unearned Revenue | 3.33 | 7.39 | 10.81 | 9.42 | 18.12 | Upgrade
|
| Other Current Liabilities | - | - | - | - | 0.38 | Upgrade
|
| Total Current Liabilities | 11.37 | 13.98 | 17.96 | 18.98 | 47.12 | Upgrade
|
| Long-Term Leases | 1.57 | 1.36 | 2.07 | 2.94 | 1.97 | Upgrade
|
| Long-Term Unearned Revenue | 12.38 | 14.43 | 18.69 | 27.73 | 32.45 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.02 | 0.27 | 0.27 | 2.08 | 2.08 | Upgrade
|
| Other Long-Term Liabilities | 43.91 | 6.16 | - | 0 | 0.03 | Upgrade
|
| Total Liabilities | 69.24 | 36.21 | 39 | 51.73 | 83.65 | Upgrade
|
| Common Stock | 515.47 | 484.72 | 451.34 | 440.28 | 434.53 | Upgrade
|
| Retained Earnings | -467 | -403.47 | -384.86 | -363.37 | -337.1 | Upgrade
|
| Comprehensive Income & Other | -3.92 | -2.88 | -3.07 | -3.57 | -5.21 | Upgrade
|
| Total Common Equity | 44.55 | 78.38 | 63.42 | 73.34 | 92.22 | Upgrade
|
| Minority Interest | -1.2 | -1.37 | -1.4 | -1.4 | -1.32 | Upgrade
|
| Shareholders' Equity | 43.35 | 77.01 | 62.02 | 71.94 | 90.9 | Upgrade
|
| Total Liabilities & Equity | 112.58 | 113.22 | 101.02 | 123.66 | 174.55 | Upgrade
|
| Total Debt | 2.42 | 2.51 | 2.95 | 3.9 | 2.8 | Upgrade
|
| Net Cash (Debt) | 53.36 | 45.29 | 32.54 | 53.98 | 55.56 | Upgrade
|
| Net Cash Growth | 17.82% | 39.19% | -39.72% | -2.84% | 47.22% | Upgrade
|
| Net Cash Per Share | 0.23 | 0.23 | 0.19 | 0.32 | 0.34 | Upgrade
|
| Filing Date Shares Outstanding | 249.09 | 228.36 | 188.53 | 170.15 | 169.71 | Upgrade
|
| Total Common Shares Outstanding | 243.12 | 220.42 | 174.99 | 170.09 | 169.48 | Upgrade
|
| Working Capital | 47.79 | 37.02 | 20.48 | 41.02 | 64.43 | Upgrade
|
| Book Value Per Share | 0.18 | 0.36 | 0.36 | 0.43 | 0.54 | Upgrade
|
| Tangible Book Value | 2.18 | 21.17 | 6.19 | 15.98 | 34.73 | Upgrade
|
| Tangible Book Value Per Share | 0.01 | 0.10 | 0.04 | 0.09 | 0.20 | Upgrade
|
| Machinery | 5.28 | 4.13 | 3.61 | 3.26 | 3.47 | Upgrade
|
| Leasehold Improvements | 2.75 | 2.3 | 2.31 | 2.15 | 2.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.